Mesothelioma Clinical Trials: Better to know these things

Image : http://www.flickr.com

Clinical trials are usually bio-medical studies in humans strictly as a default protocol. It is a process that all potential alternative treatments and drugs through the first going to be safe and effective for the general population.

Those involved in these studies are more often than non-invasive, and patients with disease resistant to treatment. Most of these patients see it as their last hope of a cure.

There are threeLevels.

Phase I is to determine the correct dosage and safety of a specific drug. This step is not efficacy but the safety test. This phase is usually tested in a small group of people, usually 20-80 people for the first time.

Phase II is whether the new drug actually works against a particular health problem. This step further evaluate the optimal dose and confirmed the results of Phase I studies. Phase II trials are to a large groupThe people, about 100-300 people.

Phase III is the final phase of clinical testing before the new drug is approved for the treatment of a disease. At this stage, the new drug against the current standard treatment for a disease is compared. various doses and combinations of drugs were tested in this phase. Up to 3,000 people are participating in the final stage.
A fourth phase is now being used for post-marketing studies. This phase will determine whether a drug or treatment to ensureThe time is done and only after all three previous phases approved by the FDA.

Medical clinical trials before any new treatment is recommended for patients. Since mesothelioma is one of the most devastating diseases, such attempt, should it be an important option for many patients, malignant mesothelioma.

There are reports of clinical trials were designed to mesothelioma of the disease and raise hope for patients with this.

PhaseIII vorinostat (SAHA) study was conducted in patients with malignant pleural mesothelioma progressive. In this study, doctors use Vorinostat, a chemotherapeutic agent to kill cancer cells stop to divide and block enzymes that cells need to grow and multiply.
Phase II pemetrexed disodium with gemcitabine or carboplatin patients with advanced malignant mesothelioma is a study to examine the effects of chemotherapeutic agents such as Disodium gemcitabine, pemetrexed,and carboplatin in advanced and recurrent malignant mesothelioma.
AZD2171 is a Phase II study in patients with unresectable malignant mesothelioma. Here the doctors to examine the application of chemotherapeutic agents, enzymes, and block the blood flow to inhibit the growth of the tumor is too slow. This study was designed to help victims suffering from mesothelioma sarcotamous, advanced and recurrent epithelial malignant cells.

Individuals who participate in clinical studies of largeare courageous people who want to take patients to mesothelioma, a more active role in support. These people make an important contribution to a deeper understanding of this disease and help further medical science, the options for treatment of mesothelioma.